Higher OS With Neoadjuvant Chemo-RT in Pancreatic Cancer
In PREOPANC, the 2-year survival rate was significantly higher for patients who received neoadjuvant chemoradiotherapy vs standard care.
Bevacizumab Rechallenge Benefit in Recurrent Ovarian Cancer?
New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
In DLBCL, Polatuzumab Combo Yields ‘Marked Improvement’ in CR, PFS, OS
Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL.
New Role for Maintenance Chemo in Rhabdomyosarcoma?
Six months of maintenance chemotherapy improved OS in children with high-risk rhabdomyosarcoma.
AR-V7 Key in Tx of mCRPC
In this video, Dr. Andrew Armstrong explains why AR-V7–positive men rarely benefit from abiraterone or enzalutamide, and advises on AR-V7 testing as a clinical tool.
Should mFOLFIRINOX Be Standard of Care in Adjuvant Tx of Pancreatic Cancer?
Compared with gemcitabine, mFOLFIRINOX improved outcomes for all endpoints when used in the adjuvant setting.
Can mRCC Patients Be Spared Debulking Nephrectomy?
In this video, Dr. Daniel George discusses CARMENA, which asked if cytoreductive surgery is necessary in the age of active systemic therapy for mRCC.
Analysis Highlights Changes in 8th Edition AJCC Melanoma Staging System
“Now that effective adjuvant therapy has arrived in melanoma, accurate staging and patient selection to optimize a risk/benefit ratio is crucial,” emphasizes lead author Max Madu.
Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Pembrolizumab Is Effective in Unresectable Melanoma, at 4-Year Follow-Up
After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma.
Determining the Role of the Gut Microbiome in Melanoma Treated With Anti–PD-1 ICIs
Patients who responded to anti–PD-1 therapy and experienced prolonged progression-free survival had a much greater diversity of gut bacteria.
Noninferiority of Neoadjuvant Chemo Cannot Be Confirmed in Ovarian Cancer Trial
The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers.
Olaparib Plus Vistusertib Promising in Early Trial of Endometrial, Other Cancers
The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.
Exploring the Changing Landscape of ICI Tx in NSCLC
In this video, Dr. Leena Gandhi discusses KEYNOTE-042, a study of pembrolizumab vs chemotherapy in NSCLC (abstract LBA4), and other key ICI trials reported at ASCO 2018.
Newer Targeted Approaches in Medullary Thyroid Cancer
In this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.
T-VEC Immunotherapy Shows Promising Early Activity in Melanoma
The genetically engineered oncolytic herpes simplex virus produced promising clinical responses in stage IIIB–IVM1a melanoma.
Steroids Diminish Survival Benefits From ICIs in Lung Cancer
Corticosteroid medications are associated with poorer outcomes of therapy with immune checkpoint inhibitors for patients with lung cancer.
Nivolumab More Effective Than Ipilimumab in Resected High-Risk Melanoma
Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab vs ipilimumab in patients with stage III and IV resected melanoma.
Adding Abemaciclib Offers Good Outcomes in Pre-/Perimenopausal Breast Cancer
The addition of abemaciclib to fulvestrant significantly improved PFS and time to subsequent chemotherapy in pre- and perimenopausal HR-positive/HER2-negative breast cancer patients.
Ribociclib Plus Fulvestrant Offers Improved PFS in Advanced Breast Cancer
The combination of ribociclib and fulvestrant yielded an improvement in progression-free survival in postmenopausal women with advanced breast cancer, according to the MONALEESA-3 trial.
Acquired Mutations in Breast Cancer Can Explain Resistance to Palbociclib/Fulvestrant
Several different driver mutations acquired during treatment for breast cancer can help explain acquired resistance to the combination of palbociclib and fulvestrant.
Women Can Safely Skip Chemotherapy for Some Early-Stage Breast Cancers
Tumor gene expression testing identifies women with certain early-stage breast cancers who can safely skip chemotherapy.
Pembrolizumab, Pemetrexed, and Carboplatin Improve Lung Cancer Survival
Adding pembrolizumab to pemetrexed and carboplatin for advanced nonsquamous NSCLC is associated with improved overall survival at 24 months.
Pembrolizumab Bests Chemotherapy in PD-L1–Expressing NSCLC
Pembrolizumab represents a new standard first-line treatment option for PD-L1–expressing advanced/metastatic NSCLC, according to KEYNOTE-042 investigators.
Lynch Syndrome Common in MSI-High Tumors
The presence of MSI-high was predictive of Lynch syndrome, which was found to be associated with a much wider spectrum of cancers than previously thought.
Taselisib Modestly Delays Progression in ER+ Breast Cancer
The PI3K inhibitor taselisib offered less dramatic clinical benefits than anticipated, and with significant toxicities.
Molecular Profiling to ID Targeted Therapies Prolongs Patient Survival
Genetic sequencing of tumors to identify targeted therapy options appears to delay tumor progression and prolong patient survival.
Blood Screening for Early-Stage Lung Cancer Possible
A simple blood draw to evaluate cfDNA might one day be used for early-stage lung cancer screening-if the mutational “noise” of normal aging can be addressed.
PFS Boost With Atezolizumab in Advanced Squamous NSCLC
The addition of atezolizumab to chemotherapy was associated with superior PFS but did not improve preliminary OS.
ASCO 2018 Highlights: GI and Hepatic Toxicities of Immune Checkpoint Inhibitor Therapy
In this podcast, ASCO Educational Book contributor Dr. Shilpa Grover, from Brigham and Women’s Hospital, describes GI and hepatic AEs encountered in patients on ICI therapy.